BTIG downgraded INmune Bio (INMB) to Neutral from Buy and removed the firm’s prior $21 price target after XPro Phase 2 data in early Alzheimer’s disease, AD. The results marks another failure of anti-inflammatory approaches in the treatment of AD – despite the clear signs of inflammation in the brains of AD patients and the decades of animal work showing that CNS-inflammation is a negative regulator of neuronal and microglial function, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio’s Xpro Alzheimer’s Trial Faces Challenges, Justifying Hold Rating
- Inmune Bio Secures $18.9 Million in Stock Offering
- INmune Bio downgraded to Neutral from Buy at Lucid Capital
- Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s
- INmune Bio downgraded to Market Perform from Outperform at Raymond James